Global Cancer Biomarkers Market Trends and Forecast.

Global Cancer Biomarkers Market Growth, Size, Trends Analysis- By Product, By Cancer Type, By Application, By Technology, By End Use – Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Published: Feb-2026	Report ID: HLCA2609	Pages: 1 - 117	Formats^*:
Category : Healthcare

According to SPER Market Research, the Global Cancer Biomarkers Market is estimated to reach USD 90.58 billion by 2034 with a CAGR 12.66%.

Introduction and Overview

The report includes an in-depth analysis of the Global Cancer Biomarkers Market, including market size and trends, product segments, applications, technologies, and supplier analysis.

The global Cancer Biomarkers Market was valued at USD 27.5 billion in 2024 and is expected to grow at a CAGR of around 12.66 % from 2025 to 2034. The market is witnessing strong growth due to the rising global incidence of cancer and increasing demand for early and accurate diagnostic solutions. Cancer biomarkers play a crucial role in detection, prognosis, drug development, and personalized medicine. Advancements in genomics, proteomics, and imaging technologies, along with expanding research initiatives, further support market expansion.

By Product:

In the Global Cancer Biomarkers Market, the consumables category holds major portion of industry revenue, as reagents, assay kits, and other disposable products are essential for routine biomarker testing in laboratories and clinical settings. These items support high-throughput diagnostics and drug development workflows, driving consistent demand. Instruments, including PCR machines and next-generation sequencing platforms, are also key contributors due to their role in sensitive and accurate detection of cancer biomarkers. Software solutions, while smaller in overall share, are increasingly important for data analysis and interpretation, particularly with advanced genomic and proteomic profiling tools.

By Cancer Type:

Within the cancer type segmentation of the market, breast cancer biomarkers account for a largest share of global revenues, driven by the high incidence of the disease and the widespread use of markers like CA 15-3 and CA 27-29 for early detection and monitoring. Biomarkers for other cancers such as prostate, colorectal, lung, cervical, and liver cancer also contribute meaningfully, but breast cancer remains a prominent focus due to disease prevalence and extensive screening programs. Ongoing research and clinical adoption of specific biomarkers for diverse cancer types further expand segment growth.

By Application Segment:

In terms of applications, diagnostics accounts for a large share of the Cancer Biomarkers Market as early and precise detection of cancer significantly improves clinical outcomes and treatment planning. Biomarker tests are widely used to identify disease presence, monitor progression, and guide therapy choices through minimally invasive methods like liquid biopsies. The drug discovery and development segment also plays a key role, leveraging biomarkers to enhance therapeutic targeting and reduce late-stage clinical failures. Personalized medicine growth further supports both diagnostics and drug development applications, enabling tailored therapies based on individual molecular profiles. Other applications continue to contribute to the broad utilization of biomarkers.

By Technology:

Among technology categories, OMICS technologies — including genomics, proteomics, and related molecular profiling methods — represent a major share of the Cancer Biomarkers Market due to their comprehensive analysis capabilities that reveal molecular alterations underlying cancer. These approaches facilitate early detection, prognosis, and therapy selection. Within OMICS, genomics and proteomics are extensively leveraged for identifying actionable biomarkers. Imaging technologies such as magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), ultrasound, and mammography complement molecular diagnostics by providing structural and functional insights, but OMICS remains central to market revenue and innovation.

By End Use:

In the Cancer Biomarkers Market, hospitals represent a key end-use category, as they integrate biomarker testing into clinical workflows for diagnosis and treatment planning, handling large patient volumes. Diagnostic laboratories also contribute significantly, offering specialized testing platforms that support high-throughput analyses and complex molecular assays. Biopharmaceutical companies use biomarkers in drug development and targeted therapy research, while academic and research institutions advance discovery and validation of novel biomarkers. Other end-use segments, including independent clinics and specialized diagnostic centers, further broaden the market’s application landscape, underscoring the diverse utility of biomarker technologies.

Regional Insights:

North America accounts for a highest share of the Global Cancer Biomarkers Market due to advanced healthcare infrastructure, strong research funding, high adoption of precision medicine, and the presence of leading biotechnology companies, particularly in the U.S. Europe also represents a considerable portion of market revenue, supported by government-backed cancer screening programs and growing investments in molecular diagnostics. Meanwhile, Asia Pacific is witnessing the fastest expansion, driven by rising cancer incidence, improving healthcare facilities, and increasing awareness in countries such as China, India, and Japan. Latin America and the Middle East & Africa show steady progress with improving diagnostic capabilities and healthcare investments.

Market Competitive Landscape:

The Cancer Biomarkers Market is highly consolidated. Some of the market key players are

Abbott Laboratories, Agilent Technologies, Bio-Rad Laboratories, Becton, Dickinson and Company, BioGenex, Centogene, F. Hoffmann-La Roche, Hologic, INOVIQ, Illumina, Merck & Co., QIAGEN, Sino Biological, Sysmex Corporation, Thermo Fisher Scientific

Recent Developments:

In August 2024, Illumina, Inc. entered FDA blessing for its in vitro individual test, TruSight Oncology Comprehensive, which analyzes over 500 genes in a case's solid excrescence. This test aimed to enhance the identification of oncology biomarkers, marking a major advancement in individualized cancer treatment by enabling more precise and targeted curatives.

Scope of the report:

Report Metric	Details
Market size available for years	2021-2034
Base year considered	2024
Forecast period	2025-2034
Segments covered	By Product, By Cancer Type, By Application, By Technology, By End Use
Regions covered	North America, Latin America, Asia-Pacific,Europe, and Middle East and , Africa
Companies Covered	bbott Laboratories; Agilent Technologies; Bio-Rad Laboratories; Becton, Dickinson and Company; BioGenex; Centogene; F. Hoffmann-La Roche; Hologic; INOVIQ; Illumina; Merck & Co.; QIAGEN; Sino Biological; Sysmex Corporation; Thermo Fisher Scientific.

Key Topics Covered in the Report

Global Cancer Biomarkers Market Size (FY’2021–FY’2034)
Overview of Global Cancer Biomarkers Market
Segmentation of Global Cancer Biomarkers Market by Product (Instruments, Consumables, Software)
Segmentation of Global Cancer Biomarkers Market by Cancer Type (Breast cancer, Prostate cancer, Colorectal cancer, Cervical cancer, Liver cancer, Lung cancer, other cancer types)
Segmentation of Global Cancer Biomarkers Market by Application (Drug discovery and development, Diagnostics, Personalized medicine, other applications)
Segmentation of Global Cancer Biomarkers Market by Technology (OMICS technologies – Proteomics, Genomics, Other OMICS technologies; Imaging technologies – Ultrasound, Computed tomography, Magnetic resonance imaging, Positron emission tomography, Mammography)
Segmentation of Global Cancer Biomarkers Market by End Use (Hospitals, Diagnostic laboratories, Biopharmaceutical companies, Academic and research institutions, other end use)
Statistical Snap of Global Cancer Biomarkers Market
Expansion Analysis of Global Cancer Biomarkers Market
Problems and Obstacles in Global Cancer Biomarkers Market
Competitive Landscape in the Global Cancer Biomarkers Market
Details on Current Investment in Global Cancer Biomarkers Market
Competitive Analysis of Global Cancer Biomarkers Market
Prominent Players in the Global Cancer Biomarkers Market
SWOT Analysis of Global Cancer Biomarkers Market
Global Cancer Biomarkers Market Future Outlook and Projections (FY’2025–FY’2034)
Recommendations from Analyst

1. Introduction

1.1. Scope of the report

1.2. Market segment analysis

2. Research Methodology

2.1. Research data source

2.1.1. Secondary Data

2.1.2. Primary Data

2.1.3. SPER’s internal database

2.1.4. Premium insight from KOL’s

2.2. Market size estimation

2.2.1. Top-down and Bottom-up approach

2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis

4.1.1. Drivers

4.1.2. Restraints

4.1.3. Opportunities

4.1.4. Challenges

5. Market variable and outlook

5.1. SWOT Analysis

5.1.1. Strengths

5.1.2. Weaknesses

5.1.3. Opportunities

5.1.4. Threats

5.2. PESTEL Analysis

5.2.1. Political Landscape

5.2.2. Economic Landscape

5.2.3. Social Landscape

5.2.4. Technological Landscape

5.2.5. Environmental Landscape

5.2.6. Legal Landscape

5.3. PORTER’s Five Forces

5.3.1. Bargaining power of suppliers

5.3.2. Bargaining power of buyers

5.3.3. Threat of Substitute

5.3.4. Threat of new entrant

5.3.5. Competitive rivalry

5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Global Cancer Biomarkers Market Manufacturing Base Distribution, Sales Area, Product Type

6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Cancer Biomarkers Market

7. Global Cancer Biomarkers Market, By Product, (USD Million) 2021-2034

7.1. Instruments

7.2. Consumables

7.3. Software

8. Global Cancer Biomarkers Market, By Cancer Type, (USD Million) 2021-2034

8.1. Breast cancer

8.2. Prostate cancer

8.3. Colorectal cancer

8.4. Cervical cancer

8.5. Liver cancer

8.6. Lung cancer

8.7. Other cancer types

9. Global Cancer Biomarkers Market, By Application, (USD Million) 2021-2034

9.1. Drug discovery and development

9.2. Diagnostics

9.3. Personalized medicine

9.4. Other applications

10. Global Cancer Biomarkers Market, By Technology, (USD Million) 2021-2034

10.1. OMICS technologies

10.1.1. Proteomics

10.1.2. Genomics

10.1.3. Other OMICS technologies

10.2. Imaging technologies

10.2.1. Ultrasound

10.2.2. Computed tomography

10.2.3. Magnetic resonance imaging

10.2.4. Positron emission tomography

10.2.5. Mammography

11. Global Cancer Biomarkers Market, By End Use, (USD Million) 2021-2034

11.1. Hospitals

11.2. Diagnostic laboratories

11.3. Biopharmaceutical companies

11.4. Academic and research institutions

11.5. Other end use

12. Global Cancer Biomarkers Market, (USD Million) 2021-2034

12.1. Global Cancer Biomarkers Market Size and Market Share

13. Global Cancer Biomarkers Market, By Region, 2021-2034 (USD Million)

13.1. Asia-Pacific

13.1.1. Australia

13.1.2. China

13.1.3. India

13.1.4. Japan

13.1.5. South Korea

13.1.6. Rest of Asia-Pacific

13.2. Europe

13.2.1. France

13.2.2. Germany

13.2.3. Italy

13.2.4. Spain

13.2.5. United Kingdom

13.2.6. Rest of Europe

13.3. Middle East and Africa

13.3.1. Kingdom of Saudi Arabia

13.3.2. United Arab Emirates

13.3.3. Qatar

13.3.4. South Africa

13.3.5. Egypt

13.3.6. Morocco

13.3.7. Nigeria

13.3.8. Rest of Middle-East and Africa

13.4. North America

13.4.1. Canada

13.4.2. Mexico

13.4.3. United States

13.5. Latin America

13.5.1. Argentina

13.5.2. Brazil

13.5.3. Rest of Latin America

14. Company Profile

14.1. Abbott Laboratories

14.1.1. Company details

14.1.2. Financial outlook

14.1.3. Product summary

14.1.4. Recent developments

14.2. Agilent Technologies

14.2.1. Company details

14.2.2. Financial outlook

14.2.3. Product summary

14.2.4. Recent developments

14.3. Bio-Rad Laboratories

14.3.1. Company details

14.3.2. Financial outlook

14.3.3. Product summary

14.3.4. Recent developments

14.4. Becton, Dickinson and Company

14.4.1. Company details

14.4.2. Financial outlook

14.4.3. Product summary

14.4.4. Recent developments

14.5. BioGenex

14.5.1. Company details

14.5.2. Financial outlook

14.5.3. Product summary

14.5.4. Recent developments

14.6. BioGenex

14.6.1. Company details

14.6.2. Financial outlook

14.6.3. Product summary

14.6.4. Recent developments

14.7. BioGenex

14.7.1. Company details

14.7.2. Financial outlook

14.7.3. Product summary

14.7.4. Recent developments

14.8. Hologic

14.8.1. Company details

14.8.2. Financial outlook

14.8.3. Product summary

14.8.4. Recent developments

14.9. INOVIQ

14.9.1. Company details

14.9.2. Financial outlook

14.9.3. Product summary

14.9.4. Recent developments

14.10. Illumina

14.10.1. Company details

14.10.2. Financial outlook

14.10.3. Product summary

14.10.4. Recent developments

14.11. Merck & Co.

14.11.1. Company details

14.11.2. Financial outlook

14.11.3. Product summary

14.11.4. Recent developments

14.12. QIAGEN

14.12.1. Company details

14.12.2. Financial outlook

14.12.3. Product summary

14.12.4. Recent developments

14.13. Sino Biological

14.13.1. Company details

14.13.2. Financial outlook

14.13.3. Product summary

14.13.4. Recent developments

14.14. Sysmex Corporation

14.14.1. Company details

14.14.2. Financial outlook

14.14.3. Product summary

14.14.4. Recent developments

14.15. Thermo Fisher Scientific

14.15.1. Company details

14.15.2. Financial outlook

14.15.3. Product summary

14.15.4. Recent developments

14.16. Others

15. Conclusion

16. List of Abbreviations

17. Reference Links

SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.

The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.

SPER-Methodology-1